Long intergenic non-protein coding RNA 1122 (LINC01122)

Long intergenic non-protein coding RNA 1122 (LINC01122) is a long intergenic non-coding RNA transcript, typically not translated into protein, and located predominantly in the cytoplasm[4]. Like other lincRNAs, LINC01122 is involved in the regulation of gene expression at various levels, including acting as a competing endogenous RNA (ceRNA) that can bind and “sponge” microRNAs, thereby modulating the expression of protein-coding targets such as TPD52[4]. LINC01122 has been identified as a prognostic marker in prostate adenocarcinoma, where its dysregulation forms part of the LINC01122/TPD52 axis, influencing tumor biology and patient outcomes. While its exact molecular roles remain incompletely characterized, LINC01122 is a representative of a growing class of lincRNAs implicated in gene regulation and cancer biology[1][3][4]. No known drugs currently target LINC01122 directly, and its role is primarily studied as a biomarker or regulatory molecule rather than as a direct therapeutic target.

Other names

FLJ30838AC007092.1LINC01793long intergenic non-protein coding RNA 1793LINC01122